David
#2
Thanks for posting. I love the slide that compares mTOR regulation of young vs. old when fasting! To replicate this regulation would require shorter half life rapalogs possibly taken at night during fasting phases.
2 Likes
AnUser
#3
This seems to show that intermittent dosing of rapamycin in mice improves lifespan.
Very good presentation. Hopefully the drug TOR101 will be affordable with a large supply if successful. Increase in cholesterol still a downside with these potential superior rapalogs. Hence it is not automatically the case that mTOR inhibitors will improve healthspan. It probably requires a cholesterol lowering drug on the side.
3 Likes
Daph
#4
This and the info about mTORC-1 selective inhibitors is fascinating. Thanks.
约瑟夫
#5
My view and comment;
If the product makes it to “Market”
The reality is most people will not have the re$ource$ to purchase{you think insurance will pick up the co$t?] as it will not be $100 per month.
More like several thousands per month.
And will be no real difference in “extending” lifespan, the difference will be the co$t.
1 Like
AnUser
#6
TOR-101, which inhibits mTORC1 and not mTORC2, has a much greater safety profile in mice and non-human primates, that’s important for a longevity drug not used for disease treatment.
Nov 18, 2024.
4 Likes
Yes, the preclinical data looks good, but still many years from us having good clinical data. I hope the trend continues.
1 Like
